PepGen: Upgrade To 'Buy' On PGN-EDODM1 Splicing Data Comeback And 2027 Milestones
PepGen Reports Phase 2 Myotonic Dystrophy Trial Results and $104.8 Million Cash Position
PepGen (NASDAQ:PEPG) Surges on Positive FREEDOM2-DM1 Data Despite In-Line Q3 Results
Loading...